Diagnostic News and Research

RSS

New study suggests nasal allergy may be involved in chronic sinus disease

Exposing patients with chronic sinus disease to allergens and then obtaining repeated images by X-ray or ultrasound reveals that nasal allergies may be involved in some cases of chronic sinus disease, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

22 Dec 2009

DR Systems announces eight new contracts with U.S. healthcare facilities

DR Systems, makers of the Unity™ RIS/PACS, today announced eight new contracts with healthcare facilities across the U.S. The contracts total more than $2.37 million. The eight facilities are:

22 Dec 2009

AAPM dispels common myths about CT scans

A panel of experts at the American Association of Physicists in Medicine (AAPM) has issued a statement calling for an open discussion of the facts about radiation hazards from computed tomography (CT) scanning in light of recent public concerns and news reports about radiation dose.

22 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Subitizing vision therapy for improving math skills

"The incidence of individuals with a mathematics learning disability is between 6-7% of the population." Since there are more than 300 million individuals in the United States, up to 21 million men, women, and children may be affected by this disorder. Sidney Groffman OD, MA, FCOVD, Professor Emeritus at SUNY College of Optometry, author of the article published in the December 2009 issue of Optometry & Vision Development, also says, "This is unfortunate because math skills are of prime importance in everyday life enabling us to understand number concepts and do calculations. Math ability is essential for many occupations and professions."

19 Dec 2009

Second wave of H1N1 virus infection in the U.S. comes to an end

Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ago may be coming to an end, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.

19 Dec 2009

CLIAWAIVED.COM expands its business into GPO market by signing the first major GPO

CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.

19 Dec 2009

Neogen reports record net income for second-quarter fiscal 2010

Neogen Corporation announced today that its net income for the second quarter of FY 2010, which ended Nov. 30, increased 18% from the previous year's second quarter. Adjusted for a 3-for-2 stock split effective Dec. 15, net income in the quarter rose to $0.20 per share, compared to the prior year's $0.17. Neogen's second quarter net income of $4,610,000 set another quarterly record for the 27-year-old company.

19 Dec 2009

Canada Health Infoway reaches a PSA with Agfa HealthCare for its IMPAX 6 PACS and DI-r systems

Canada Health Infoway (Infoway) and Agfa HealthCare, a leading provider of diagnostic imaging solutions, have reached a Preferred Solution Agreement (PSA) providing preferential conditions and pricing for Agfa HealthCare's IMPAX(TM) 6 Picture Archiving and Communication System (PACS) and Viewer as well as its IMPAX(TM) Data Center and Diagnostic Imaging Repository (DI-r). This is the second time Infoway and Agfa HealthCare have achieved a Preferred Solution Agreement.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

Alliance HealthCare Services provides financial guidance for full-year 2010

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, reaffirmed 2009 guidance and announced financial guidance for full year 2010.

18 Dec 2009

Triage NGAL bedside blood test helps identify AKI risk: New study

According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.

18 Dec 2009

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

18 Dec 2009

Adimab announces initiation of research collaborations with two other companies

Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of research collaborations with Pfizer and an undisclosed second company. Adimab also announced the receipt of milestone payments from two recently announced discovery collaborations with Merck and Roche.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Revolutions Medical Corporation, producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more.

17 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009